Vasopressin
Vasopressin, Vasostrict (vasopressin) is a protein pharmaceutical. Vasopressin was first approved as Vasostrict on 2014-04-17.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vasopressin, Vasostrict (discontinued: Pitressin, Vasostrict)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vasopressin tannate
Vasopressin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VASOPRESSIN | American Regent | N-212593 RX | 2020-08-03 | 2 products, RLD, RS |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Baxter | N-217569 RX | 2023-09-29 | 2 products, RLD, RS |
| VASOSTRICT | Endo | N-204485 RX | 2014-04-17 | 4 products, RLD, RS |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Long Grove Pharmaceuticals | N-217766 RX | 2024-07-11 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vasopressin | New Drug Application | 2024-10-31 |
| vasopressin in 0.9% sodium chloride | New Drug Application | 2024-09-06 |
| vasostrict | New Drug Application | 2023-11-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Vasopressin, Vasostrict, Par Sterile Products | |||
| 9375478 | 2035-01-30 | U-1857 | |
| 9687526 | 2035-01-30 | U-1857 | |
| 9744209 | 2035-01-30 | U-1857 | |
| 9744239 | 2035-01-30 | U-1857 | |
| 9750785 | 2035-01-30 | DP | |
| 9919026 | 2035-01-30 | DP | |
| 9925233 | 2035-01-30 | U-1857 | |
| 9925234 | 2035-01-30 | U-1857 | |
| 9937223 | 2035-01-30 | U-1857 | |
| 9962422 | 2035-01-30 | U-1857 | |
| 9968649 | 2035-01-30 | U-1857 | |
| 9974827 | 2035-01-30 | U-1857 | |
| 9981006 | 2035-01-30 | U-1857 | |
| 10010575 | 2035-01-30 | U-1857 | |
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03X: Other diuretics in atc
— C03XA: Vasopressin antagonists, diuretics
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BA: Vasopressin and analogues
— H01BA01: Vasopressin (argipressin)
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Vasopressin |
| INN | vasopressin injection |
| Description | Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+). |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 113-79-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL373742 |
| ChEBI ID | 34543 |
| PubChem CID | 644077 |
| DrugBank | DB00067 |
| UNII ID | Y87Y826H08 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Vasopressin – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use